Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 21, 2023

DPP4 Inhibitors Confer Increased Odds of Bullous Pemphigoid Even Years After Drug Initiation in Patients With Diabetes

Archives of Dermatological Research


Additional Info

Archives of Dermatological Research
Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
Arch Dermatol Res 2023 Jan 01;315(1)33-39, K Kridin, O Avni, G Damiani, D Tzur Bitan, E Onn, O Weinstein, AD Cohen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading